Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
12 Nov 2013

Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that BioAgilytix Labs, a contract research organization (CRO) specializing in immunoassays and cell-based assays, based in Durham, North Carolina, has invested in two Gyrolab™ xP workstations to support its bioanalysis services.

Dr. Afshin Safavi, Founder and Chief Scientific Officer at BioAgilytix Labs, said: “As a trusted partner to six of the top ten global pharmaceutical and biotech companies, it is vital that we broaden our technology offering and continue to deliver the highest quality bioanalysis possible. In the hands of our highly experienced scientists, the Gyros platform will allow BioAgilytix to continue to provide the quality data our customers have grown to expect, while also meeting growing capacity demands. Moreover, the nanoliter scale of the platform enables us to generate such data from small volumes of precious sample, maximizing the number of assays that can be performed.”

“Major biopharmaceutical companies are increasingly desiring that immunoassay testing be developed and completed using Gyrolab xP workstations due to its high precision, low sample volumes, and ease with which assays can be transferred,” commented Dan Calvo, CEO at Gyros. “We are delighted that BioAgilytix has adopted the Gyros platform and are confident it will enable them to continue to provide their customers with high quality bioanalysis.”

Gyros platform comprises Gyrolab workstation, control and evaluation software, and the unique microfluidic Gyrolab Bioaffy CDs in which immunoassay steps are integrated and run at nanoliter scale.

Request Info


Company website

Gyros AB
profile photo

Sarah Thomas
Editorial Assistant